Monitoring Minimal Residual Disease in the Myeloproliferative Neoplasms: Current Applications and Emerging Approaches

The presence of acquired mutations within the JAK2, CALR, and MPL genes in the majority of patients with myeloproliferative neoplasms (MPN) affords the opportunity to utilise these mutations as markers of minimal residual disease (MRD). Reduction of the mutated allele burden has been reported in res...

Descripción completa

Detalles Bibliográficos
Autores principales: Haslam, Karl, Langabeer, Stephen E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2016
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5093244/
https://www.ncbi.nlm.nih.gov/pubmed/27840830
http://dx.doi.org/10.1155/2016/7241591

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5093244/
https://www.ncbi.nlm.nih.gov/pubmed/27840830
http://dx.doi.org/10.1155/2016/7241591

Ejemplares similares